Effects of ranolazine on cloned cardiac Kv4.3 potassium channels

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 3, 2011, Pages 952-958

  Kim, Hee Jae ^a   Ahn, Hye Sook ^a   Choi, Jin Sung ^a   Choi, Bok Hee ^b   Hahn, Sang June ^a  

^a The Catholic University of Korea   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL KV4.3; RANOLAZINE; SHAL POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DISSOCIATION CONSTANT; ELECTRIC POTENTIAL; HYPERPOLARIZATION; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PREPULSE INHIBITION; PRIORITY JOURNAL; STEADY STATE; WHOLE CELL;

ACETANILIDES; ANGINA PECTORIS; ANIMALS; CHO CELLS; CLONE CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; KINETICS; MYOCARDIUM; PATCH-CLAMP TECHNIQUES; PIPERAZINES; SHAL POTASSIUM CHANNELS; SOFTWARE; TRANSFECTION;

EID: 81555204275     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.184176     Document Type: Article

References (47)

1. Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, Jo YH, Kim MS, Sung KW, and Hahn SJ (2006) Interaction of riluzole with the closed inactivated state of Kv4.3 channels. J Pharmacol Exp Ther 319:323-331.
2. Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Goodrow RJ Jr, et al. (2004a) Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 9 (Suppl 1):S65-S83. (Pubitemid 39334836)
3. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, and Thomas G (2004b) Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110:904-910. (Pubitemid 39136212)
4. Barry DM, Xu H, Schuessler RB, and Nerbonne JM (1998) Functional knockout of the transient outward current, long-QT syndrome, and cardiac remodeling in mice expressing a dominant-negative Kv4 α subunit. Circ Res 83:560-567. (Pubitemid 28411058)
5. Bean BP, Cohen CJ, and Tsien RW (1983) Lidocaine block of cardiac sodium channels.J Gen Physiol 81:613-642.
6. Birnbaum SG, Varga AW, Yuan LL, Anderson AE, Sweatt JD, and Schrader LA (2004) Structure and function of Kv4-family transient potassium channels. Physiol Rev 84:803-833.
7. Brendel J and Peukert S (2003) Blockers of the Kv1.5 channel for the treatment ofatrial arrhythmias. Curr Med Chem Cardiovasc Hematol Agents 1:273-287.
8. Butterworth JF 4th and Strichartz GR (1990) Molecular mechanisms of local anesthesia:a review. Anesthesiology 72:711-734.
9. Caballero R, Pourrier M, Schram G, Delpón E, Tamargo J, and Nattel S (2003) Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines. Br J Pharmacol 138:1475-1484. (Pubitemid 36609643)
10. Chaitman BR (2002) Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor.Curr Probl Cardiol 27:527-555.
11. Chaitman BR (2006) Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 113:2462-2472.
12. Connor JA and Stevens CF (1971) Voltage clamp studies of a transient outward membrane current in gastropod neural somata. J Physiol 213:21-30.
13. Courtney KR (1975) Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol ExpTher 195:225-236.
14. + channel in ventricular muscle. A molecularcorrelate for the transient outward current. Circ Res 79:659-668.
15. Eckhardt LL, Teelin TC, and January CT (2008) Is ranolazine an antiarrhythmic drug? Am J Physiol Heart Circ Physiol 294:H1989-H1991.
16. Friederich P and Solth A (2004) Interaction of ropivacaine with cloned cardiac Kv4.3/KChIP2.2 complexes. Anesthesiology 101:1347-1356. (Pubitemid 39564991)
17. Gaborit N, Le Bouter S, Szuts V, Varro A, Escande D, Nattel S, and Demolombe S (2007) Regional and tissue specific transcript signatures of ion channel genes inthe non-diseased human heart. J Physiol 582:675-693. (Pubitemid 47040552)
18. Jacobs ER and DeCoursey TE (1990) Mechanisms of potassium channel block in rat alveolar epithelial cells. J Pharmacol Exp Ther 255:459-472.
19. Josephson IR (1988) Lidocaine blocks Na, Ca and K currents of chick ventricular myocytes. J Mol Cell Cardiol 20:593-604.
20. Kass RS and Cabo C (2000) Channel structure and drug-induced cardiac arrhythmias.Proc Natl Acad Sci U S A 97:11683-11684.
21. Kim HJ, Ahn HS, Choi BH, and Hahn SJ (2011) Inhibition of Kv4.3 by genistein via a tyrosine phosphorylation-independent mechanism. Am J Physiol Cell Physiol 300:C567-C575.
22. Kirsch GE, Yeh JZ, and Oxford GS (1986) Modulation of aminopyridine block of potassium currents in squid axon. Biophys J 50:637-644. (Pubitemid 16028171)
23. Kodama I, Wilde A, Janse MJ, Durrer D, and Yamada K (1984) Combined effects of hypoxia, hyperkalemia and acidosis on membrane action potential and excitability of guinea-pig ventricular muscle. J Mol Cell Cardiol 16:247-259. (Pubitemid 14168016)
24. Lenkowski PW, Ko SH, Anderson JD, Brown ML, and Patel MK (2004) Block of human NaV1.5 sodium channels by novel α-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci 21:635-644. (Pubitemid 38447145)
25. MacInnes A, Fairman DA, Binding P, Rhodes J, Wyatt MJ, Phelan A, Haddock PS, and Karran EH (2003) The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93:e26-32.
26. McCormack JG, Stanley WC, and Wolff AA (1998) Ranolazine: a novel metabolic modulator for the treatment of angina. Gen Pharmacol 30:639-645. (Pubitemid 28167764)
27. + channel diversity in the mammalian myocardium. J Physiol 525:285-298.
28. + channel α-subunit, Kv4.3 in the rat. FEBS Lett 420:47-53.
29. Pepine CJ and Wolff AA (1999) A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 84:46-50. (Pubitemid 29307639)
30. Rajamani S, El-Bizri N, Shryock JC, Makielski JC, and Belardinelli L (2009) Usedependent block of cardiac late Na+ current by ranolazine. Heart Rhythm 6:1625- 1631.
31. Rajamani S, Shryock JC, and Belardinelli L (2008) Rapid kinetic interactions of ranolazine with HERG K+ current. J Cardiovasc Pharmacol 51:581-589.
32. Rolf S, Haverkamp W, Borggrefe M, Musshoff U, Eckardt L, Mergenthaler J, Snyders DJ, Pongs O, Speckmann EJ, Breithardt G, et al. (2000) Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes. Naunyn Schmiedebergs Arch Pharmacol 362:22-31. (Pubitemid 30431632)
33. Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, and Nattel S (2004) Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 142:1300-1308. (Pubitemid 39185852)
34. + channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J Pharmacol Exp Ther 269:66-74.
35. Snyders DJ (1999) Structure and function of cardiac potassium channels. Cardiovasc Res 42:377-390.
36. Snyders DJ, Tamkun MM, and Bennett PB (1993) A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol 101:513-543. (Pubitemid 23123420)
37. Snyders DJ and Yeola SW (1995) Determinants of antiarrhythmic drug action. Electrostatic and hydrophobic components of block of the human cardiac hKv1.5 channel. Circ Res 77:575-583.
38. Solth A, Siebrands CC, and Friederich P (2005) Inhibition of Kv4.3/KChIP2.2 channels by bupivacaine and its modulation by the pore mutation Kv4.3V401I. Anesthesiology 103:796-804. (Pubitemid 41415528)
39. Valdivia CR, Chu WW, Pu J, Foell JD, Haworth RA, Wolff MR, Kamp TJ, and Makielski JC (2005) Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol 38:475-483. (Pubitemid 40331938)
40. Wang DW, Yazawa K, Makita N, George AL Jr, and Bennett PB (1997) Pharmacological targeting of long QT mutant sodium channels. J Clin Invest 99:1714-1720. (Pubitemid 27163823)
41. Wang GK, Calderon J, and Wang SY (2008) State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na- channel isoforms by ranolazine. Mol Pharmacol 73:940-948. (Pubitemid 351397898)
42. Wang Z, Fermini B, and Nattel S (1995) Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther 272:184-196.
43. + channels of dorsal root ganglion neurons by the long-duration anesthetic butamben. J Pharmacol Exp Ther 314:1177-1186.
44. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, and Belardinelli L (2004) Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 310:599-605. (Pubitemid 38992327)
45. Wulff H, Castle NA, and Pardo LA (2009) Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 8:982-1001.
46. Yeh JZ, Oxford GS, Wu CH, and Narahashi T (1976) Dynamics of aminopyridine block of potassium channels in squid axon membrane. J Gen Physiol 68:519-535.
47. Yu M and Chen L (2008) Modulation of major voltage- and ligand-gated ion channels in cultured neurons of the rat inferior colliculus by lidocaine. Acta Pharmacol Sin 29:1409-1418.